New eye injection shows promise for Diabetes-Related vision loss

NCT ID NCT05959304

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested the safety and effectiveness of brolucizumab, a drug injected into the eye, for treating diabetic macular edema (DME) in 66 Indian patients. DME is a complication of diabetes that can cause vision loss. The study aimed to see how well the drug works in real-world conditions, not just in controlled trials. Results will help doctors understand if brolucizumab is a good option for managing DME.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: brolucizumab (injected into the eye)
What this could lead to: If successful, this could confirm that brolucizumab is a safe and effective option for managing diabetic macular edema in real-world patients.
What could go wrong: This is a small, completed phase IV study with only 66 participants, so results may not apply to all patients. As with any eye injection, there are risks like infection or inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic macular edema Macular Edema vision disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETIC MACULAR EDEMA

Contacts and locations

Locations

Novartis Investigative Site

Ahmedabad, Gujarat, 380052, India
Novartis Investigative Site

Bangalore, Karnataka, 560 010, India
Novartis Investigative Site

Kochi, Kerala, 682 026, India
Novartis Investigative Site

Chennai, Tamil Nadu, 600045, India
Novartis Investigative Site

Kolkata, West Bengal, 700 073, India
Novartis Investigative Site

Coimbatore, 641002, India
Novartis Investigative Site

Kolkata, 700120, India
Novartis Investigative Site

New Delhi, 110029, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.